Experimental targeted therapy shows early promise against medulloblastomas

Researchers from St. Jude Children's Research Hospital and the Paediatric Brain Tumour Consortium (PBTC) presented at the American Society of Clinical Oncology the findings of a paediatric brain tumour study using an experimental drug that targets the underlying genetic makeup of the tumour. The research focused on a new way to attack the tumours by blocking the Hedgehog pathway that is linked to approximately 20 percent of medulloblastomas...

Read the whole article on

More from